CTLA4 and metastatic melanoma: A phase 1 clinical trial reported an ORR of 19.6% for metastatic melanoma patients treated with ipilimumab, an anti-CTLA-4 antibody, in combination with the angiogenesis inhibitor bevacizumab (27).